Journal Article Review Research Support, N.I.H., Extramural Ppublish 134 citations
PubMed: 39242276 DOI: 10.1016/j.trecan.2024.07.009
CD4 + T cells in antitumor immunity.
Trends Cancer 10(10):969-985
Authors: Elena Montauti, David Y Oh, Lawrence Fong
Affiliations
- Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
- Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Immunotherapy Integrated Research Center, Fred Hutchison Cancer Center, Seattle, WA, USA.
Abstract
Advances in cancer immunotherapy have transformed cancer care and realized unprecedented responses in many patients. The growing arsenal of novel therapeutics - including immune checkpoint inhibition (ICI), adoptive T cell therapies (ACTs), and cancer vaccines - reflects the success of cancer immunotherapy. The therapeutic benefits of these treatment modalities are generally attributed to the enhanced quantity and quality of antitumor CD8 + T cell responses. Nevertheless, CD4 + T cells are now recognized to play key roles in both the priming and effector phases of the antitumor immune response. In addition to providing T cell help through co-stimulation and cytokine production, CD4 + T cells can also possess cytotoxicity either directly on MHC class II-expressing tumor cells or to other cells within the tumor microenvironment (TME). The presence of specific populations of CD4 + T cells, and their intrinsic plasticity, within the TME can represent an important determinant of clinical response to immune checkpoint inhibitors, vaccines, and chimeric antigen receptor (CAR) T cell therapies. Understanding how the antitumor functions of specific CD4 + T cell types are induced while limiting their protumorigenic attributes will enable more successful immunotherapies.
MeSH
Cells, Vaccines, Neoplasms, Immunotherapy, Immunity, Therapeutics
Cited by
- Orchestrated Cu 2+-coordinated tetracycline-porphyrin self-assembly remodels tumor microenvironment for photo-enhanced immuno-chemodynamic therapy. J Nanobiotechnology, 2025
- Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling. Front Immunol, 2025
- The Bidirectional Interplay between T Cell-Based Immunotherapies and the Tumor Microenvironment. Cancer Immunol Res, 2025
- Generalizable AI predicts immunotherapy outcomes across cancers and treatments. medRxiv, 2025
- B-Cell Lymphomas Secrete Novel Inhibitory Molecules That Disrupt HLA Class II-Mediated CD4+ T-Cell Recognition. Cells, 2025
- Spatial transcriptomics and scRNA-seq: decoding tumor complexity and constructing prognostic models in colorectal cancer. Hum Genomics, 2025
- Systemic immune response induced by radiofrequency ablation versus microwave ablation at varying powers in murine models of hepatocellular carcinoma. Transl Cancer Res, 2025
- Exploring the Role of Thioredoxin system in Cancer Immunotherapy. J Cancer, 2025
- Early-Stage Luminal B-like Breast Cancer Exhibits a More Immunosuppressive Tumor Microenvironment than Luminal A-like Breast Cancer. Biomolecules, 2025
- Uracil-DNA glycosylase deficiency is associated with repressed tumor cell-intrinsic inflammatory signaling and altered sensitivity to exogenous interferons. bioRxiv, 2025
- Tumor Microenvironment in Melanoma-Characteristic and Clinical Implications. Int J Mol Sci, 2025
- Transcriptomic signatures in peripheral CD4T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation. Front Immunol, 2025
- Combination therapy with alisertib enhances the anti-tumor immunity induced by a liver cancer vaccine. iScience, 2025
- CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors. J Immunother Cancer, 2025
- UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity. Cell Rep Med, 2025
- T cells in cancer: mechanistic insights and therapeutic advances. Biomark Res, 2025
- The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis. Sci Rep, 2025
- A pan-cancer analysis reveals the oncogenic and immunological role of insulin-like growth factor 2 mRNA-binding protein family members. Discov Oncol, 2025
- G6PC1 expression as a prognostic biomarker associated with metabolic reprogramming and tumor microenvironment in hepatocellular carcinoma. Front Immunol, 2025
- GPR55 in the tumor microenvironment of pancreatic cancer controls tumorigenesis. Front Immunol, 2025